Literature DB >> 23359755

Expression and Distribution Characteristics of Human Ortholog of Mammalian Enabled (hMena) in Glioma.

Xue-Tao Dong1, Xue-Jun Yang, Hua-Min Wang, Wei Wang, Li Yu, Bin Zhang, Sheng-Ping Yu, Hao-Lang Ming.   

Abstract

OBJECTIVE: To investigate the utility of hMena, a family of enabled/vasodilator-stimulated phosphoprotein (Ena/VASP), we sought to characterize the expression profile and distribution characteristics of hMena in a large panel of glioma samples and determine whether hMena expression levels might correlate with the pathological grade of glioma.
METHODS: Sixty-five specimens of glioma with different pathological grades and five control brain tissues were collected. In 6 of the 21 glioblastoma patients, multi-specimens were obtained respectively from the main tumor mass, the junction zone between the tumor and the normal tissue, and adjacent brain tissue 1.5 cm away from the tumor boundary under assistance of neuronavigation system during the operation. Immunohistochemistry was used to detect the expression and distribution characteristics of hMena. hMena expression was analyzed by Western blot in 20 specimens.
RESULTS: The hMena expression was negative in control brain tissue but positive in different grades of glioma. The expression rate of hMena was positively correlated with the increasing grade of the World Health Orgnization (WHO) classification (r(s)=0.682, P=0.000). hMena was located in cytoplasm. Positive cells only distributed around the vessels within the tumor mass in low grade glioma, while in high grade glioma, these cells were able to be detected not only in the tumor but also in the boundary zone and adjacent brain parenchyma. In the tumor mass, hMena expressed highly and diffusedly. In the junction zone, hMena positive cells formed radiolitic pattern around the vessels. In adjacent brain parenchyma, single positive cell was scattered. hMena expression was markedly elevated in Grade III and IV glioma compared with Grade II and I.
CONCLUSION: Our data suggested that the expression of hMena is closely related to malignant grade of glioma. hMena can label the migrating cells, and indicate the migrating path of glioma cells from the tumor to adjacent tissue along with the vascular basement membranes and tracts of white matter.

Entities:  

Keywords:  Glioma; Immunohistochemistry; Migration; hMena

Year:  2011        PMID: 23359755      PMCID: PMC3551309          DOI: 10.1007/s11670-011-0312-z

Source DB:  PubMed          Journal:  Chin J Cancer Res        ISSN: 1000-9604            Impact factor:   5.087


  23 in total

Review 1.  Epithelial-mesenchymal transitions in tumour progression.

Authors:  Jean Paul Thiery
Journal:  Nat Rev Cancer       Date:  2002-06       Impact factor: 60.716

Review 2.  Role of integrins in cell invasion and migration.

Authors:  John D Hood; David A Cheresh
Journal:  Nat Rev Cancer       Date:  2002-02       Impact factor: 60.716

3.  [Correlation between the distribution of CD133-positive cells and the proliferation of microvessels in glioblastoma multiforme].

Authors:  Hua-min Wang; Xue-jun Yang; Xue-tao Dong; Yu Li; Wei Wang; Hao-lang Ming; Bin Zhang; Sheng-ping Yu
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2011-03-22

4.  A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha.

Authors:  Sascha Seidel; Boyan K Garvalov; Valtteri Wirta; Louise von Stechow; Anne Schänzer; Konstantinos Meletis; Marietta Wolter; Daniel Sommerlad; Anne-Theres Henze; Monica Nistér; Guido Reifenberger; Joakim Lundeberg; Jonas Frisén; Till Acker
Journal:  Brain       Date:  2010-04       Impact factor: 13.501

5.  MGMT gene silencing and benefit from temozolomide in glioblastoma.

Authors:  Monika E Hegi; Annie-Claire Diserens; Thierry Gorlia; Marie-France Hamou; Nicolas de Tribolet; Michael Weller; Johan M Kros; Johannes A Hainfellner; Warren Mason; Luigi Mariani; Jacoline E C Bromberg; Peter Hau; René O Mirimanoff; J Gregory Cairncross; Robert C Janzer; Roger Stupp
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

6.  Critical roles of phosphorylation and actin binding motifs, but not the central proline-rich region, for Ena/vasodilator-stimulated phosphoprotein (VASP) function during cell migration.

Authors:  Joseph J Loureiro; Douglas A Rubinson; James E Bear; Gretchen A Baltus; Adam V Kwiatkowski; Frank B Gertler
Journal:  Mol Biol Cell       Date:  2002-07       Impact factor: 4.138

7.  Mena and vasodilator-stimulated phosphoprotein are required for multiple actin-dependent processes that shape the vertebrate nervous system.

Authors:  A Sheila Menzies; Attila Aszodi; Scott E Williams; Alexander Pfeifer; Ann M Wehman; Keow Lin Goh; Carol A Mason; Reinhard Fassler; Frank B Gertler
Journal:  J Neurosci       Date:  2004-09-15       Impact factor: 6.167

Review 8.  Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. Class III beta-tubulin.

Authors:  Christos D Katsetos; Eduarda Dráberová; Agustin Legido; Charles Dumontet; Pavel Dráber
Journal:  J Cell Physiol       Date:  2009-12       Impact factor: 6.384

Review 9.  Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. II. gamma-Tubulin.

Authors:  Christos D Katsetos; Eduarda Dráberová; Agustin Legido; Pavel Dráber
Journal:  J Cell Physiol       Date:  2009-12       Impact factor: 6.384

10.  Human Mena protein, a serex-defined antigen overexpressed in breast cancer eliciting both humoral and CD8+ T-cell immune response.

Authors:  Francesca Di Modugno; Giovanna Bronzi; Matthew J Scanlan; Duilia Del Bello; Simona Cascioli; Irene Venturo; Claudio Botti; Maria Rita Nicotra; Marcella Mottolese; Pier Giorgio Natali; Angela Santoni; Elke Jager; Paola Nisticò
Journal:  Int J Cancer       Date:  2004-05-10       Impact factor: 7.396

View more
  1 in total

1.  Characterization, survival analysis, and expression of IGFR in tumor samples from patients diagnosed with Ewing family tumors treated at the Barretos Cancer Hospital.

Authors:  Adriano Jander Ferreira; Erica Boldrini; Rossana Verónica Mendoza López; Cristovam Scapulatempo Neto; Julie Francine Cerutti Santos; Luiz Fernando Lopes
Journal:  Rev Bras Ortop       Date:  2016-12-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.